AI Image
Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
CNBC • • business
Key Points:
- Kimberly-Clark completed its $49 billion acquisition of Tylenol maker Kenvue, expanding its presence in health and wellness amid rising consumer focus on healthy lifestyles.
- CEO Michael Hsu emphasized plans to accelerate Kenvue's growth by leveraging Kimberly-Clark's stronger consumer packaged goods capabilities, including improvements in e-commerce, retail relationships, and product innovation.
- The company faces challenges managing higher input costs due to geopolitical tensions while keeping products affordable for middle- and lower-income consumers, aiming to offset costs through pricing discipline and cost reductions.
- Legal risks related to Tylenol's alleged prenatal use effects persist, but Hsu defended the brand's safety based on extensive research and noted recent sales momentum and new FDA-approved product innovations.
- Kimberly-Clark reaffirmed its commitment to maintaining its dividend, a key attraction for investors, expecting earnings accretion by year two and aiming to reduce leverage while preserving its single-A credit rating.
